Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.
Saved in:
| Title: | Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. |
|---|---|
| Authors: | Dimitriou F; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland. Electronic address: florentia.dimitriou@usz.ch., Orloff MM; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Koch Hein EC; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Departments of Medicine and Immunology, University of Toronto, Toronto, Canada; Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Cheng PF; Department of Oncology, Geneva University Hospital, Geneva, Switzerland., Hughes IF; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., Simeone E; Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy., Montazeri K; Massachusetts General Hospital, Harvard Medical School, Boston, USA., Grover P; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Mehmi I; The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, USA., Gerard CL; Precision Oncology Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Gaudy-Marqueste C; Dermatology and Skin Cancer Department, Aix-Marseille University, Marseille, France., Grob JJ; Dermatology and Skin Cancer Department, Aix-Marseille University, Marseille, France., Michielin O; Department of Oncology, Geneva University Hospital, Geneva, Switzerland., Hamid O; The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, USA., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Camperdown, Australia., Sullivan R; Massachusetts General Hospital, Harvard Medical School, Boston, USA., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands., Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA., Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy., Joshua AM; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital Sydney and Garvan Institute of Medical Research, Sydney, New South Wales, Australia., Carvajal RD; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., Butler MO; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Departments of Medicine and Immunology, University of Toronto, Toronto, Canada., Hassel JC; Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany., Dummer R; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland. |
| Source: | European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Jan; Vol. 214, pp. 115161. Date of Electronic Publication: 2024 Nov 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
